NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Motilal Oswal Maintains BUY Rating on Inventurus Knowledge Solutions Amid Acquisition of TruBridge

Inventurus Knowledge Solutions (IKS) has announced the acquisition of TruBridge, a leading healthcare IT and Revenue Cycle Management (RCM) services provider in the US. The acquisition is significant as TruBridge's revenue of USD347 million in calendar year 2025 is nearly equal to IKS's revenue base. This deal is expected to diversify IKS's business into the sticky Software as a Service (SaaS) Electronic Health Record (EHR) segment.

The acquisition also brings on board ~3,700 employees, which implies a revenue per employee of ~USD94,000. In contrast, IKS has ~26,000 employees, resulting in a revenue per employee of ~USD26,000. Furthermore, TruBridge operates at significantly lower margins than IKS, indicating a strong potential for margin expansion. TruBridge is a significant player in the rural hospital EHR market, serving more than 700 community and critical access hospitals.

The acquisition will enable IKS to offer an integrated suite of Electronic Medical Record (EMR) and care enablement platform solutions to both existing and new clients. TruBridge's data and technology assets, including its Healthcare Financial Management Association (HFMA) peer-reviewed suite of RCM offerings and EHR solutions, will also strengthen IKS's capabilities as a technology-led, data-driven healthcare services group.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

CompanyRevenue (USDm)Revenue per Employee (USD)
IKS~26,000
TruBridge347~94,000

Outlook

The research report has not yet incorporated TruBridge's numbers into valuation as it will be margin and profit dilutive due to the relatively low margin profile and a debt-funded structure. Consequently, Motilal Oswal reiterates its BUY rating on the stock with a Target Price (TP) of INR1,902, based on 30x FY28E EPS.

Investor Takeaway

Investors should consider the potential for margin expansion and diversification into the SaaS EHR segment.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.